Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma, a randomised phase III study (CAIRO3 study)
- Registry ID
- EUCTR2006-006657-27
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE3
- Sponsor
- Dutch Colorectal Cancer Group
- Start date
- 2006-12-20
- Last update
- 2026-08-16
Conditions
- Advanced colorectal carcinoma
Summary
To assess the progression-free survival (PFS2) after re-introduction of MTD chemotherapy after observation (arm A) versus maintenance treatment with low-dose capecitabine plus bevacizumab (arm B) in patients with advanced colorectal cancer with stable disease or better after induction treatment with capecitabine, oxaliplatin, and bevacizumab.
Locations
View on source registry